(Q46397863)

21 December 2017

title

Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword? (English)

1 reference

21 December 2017

1 reference

cardiovascular disease

1 reference

David Pereg

1

1 reference

21 December 2017

Michael Lishner

series ordinal

2

1 reference

21 December 2017

publication date

1 September 2008

1 reference

21 December 2017

published in

European Heart Journal

1 reference

21 December 2017

volume

29

1 reference

21 December 2017

issue

19

1 reference

21 December 2017

page(s)

2325-2326

1 reference

21 December 2017

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN384

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN384

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN384

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN384

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN384

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN384

Bevacizumab, bleeding, thrombosis, and warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN384

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN384

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN384

Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHN384

21 January 2018

Identifiers

DOI

10.1093/EURHEARTJ/EHN384

1 reference

21 December 2017

1 reference

21 December 2017